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N-Myc is a member of the Myc family of transcription
factors that have been shown to play a pivotal role in
cell proliferation and differentiation. In this report, we
have investigated the relationship between N-Myc and
the developmental control gene Pax-3. Using transient
transfection assays, we show that the Pax-3 promoter is
activated by both N-Myc-Max and c-Myc-Max. Moreover,
we show that Myc regulation of Pax-3 promoter activity
is dependent upon a noncanonical E box site in the 5
promoter region of Pax-3. In addition, we show that
ectopic expression of both N-Myc and c-Myc leads to
increased expression of Pax-3 mRNA. Furthermore, we
show that Pax-3 mRNA expression is cell cycle-regu-
lated and that the 5 promoter region of Pax-3 (bp 1578
to 56) can direct cell cycle-dependent gene expression
with kinetics similar to that of the endogenous tran-
script. Site-directed mutagenesis of the E box site within
the Pax-3 promoter significantly altered the pattern of
expression through the cell cycle. These results suggest
that the Myc family of transcription factors may modu-
late Pax-3 expression in vivo.
N-Myc is a member of the Myc family of transcription factors
(c-Myc, N-Myc, L-Myc, B-Myc, and S-Myc) that are character-
ized by a basic DNA binding domain and dimerization domain
composed of a helix-loop-helix and leucine zipper. Members of
this family have been shown to play a pivotal role in cell
proliferation and terminal differentiation. The forced expres-
sion of c-Myc promotes progression into S phase and inhibits
differentiation and entry into a quiescent state (1). Further-
more, the deregulation of myc gene expression has been impli-
cated in the pathogenesis of several tumor types. The human
NMYC gene is frequently amplified in neuroblastoma, a child-
hood cancer of neural crest origin (2, 3). NMYC amplification in
this cancer is associated with rapid tumor progression, ad-
vanced stages, and poor prognosis.
N-myc shares many of the properties of c-myc, although
unlike c-myc, whose expression appears to be ubiquitous,
N-myc is primarily expressed during early embryogenesis (4).
In mice, N-myc expression is highest around E9.5, where ex-
pression is observed in early neural crest lineages, limb buds,
and developing central nervous system (5). The expression of
N-myc then declines in these tissues upon the onset of differ-
entiation. The importance of N-myc in embryogenesis is dem-
onstrated by the finding that homozygous N-myc null mice die
around embryonic day 11.5 with abnormalities in the limb buds
and in the central and peripheral nervous systems (6). Most
notably, the N-myc-deficient embryos showed a great reduction
in the number of mature neurons, especially those derived from
the neural crest such as sensory and sympathetic neurons.
These defects occurred despite compensatory c-Myc increases
(7), suggesting a unique role for N-Myc in development.
To function, N-Myc, like c-Myc, must heterodimerize with
Max proteins. Max proteins also contain a basic DNA binding
domain and a helix loop helix and leucine zipper dimerization
motif (8). This heterodimerization is required for sequence
specific DNA binding as well as for biological function. Myc-
Max heterodimers recognize the core sequence CA(C/T)GTG,
termed the E box Myc sequence. In both yeast and mammalian
cells, Myc-Max complexes are capable of activating reporter
gene constructs containing concatamerized E box Myc sites (9,
10). In addition, Max proteins can also heterodimerize with
Mad proteins that negatively regulate cell growth. Max-Mad
complexes bind to the same E box motif as the Myc-Max com-
plexes, but in contrast to Myc-Max complexes, they repress
transcription (11). Mad family members repress transcription
through their association with the Sin3 proteins, which in turn
recruit histone deacetylases to the complex (12). The central
member of the Myc/Max/Mad network is Max, which is very
stable. In contrast, the expressions of both Myc and Mad pro-
teins are highly regulated. The myc genes are actively tran-
scribed in dividing cells, but little expression can be detected in
quiescent or differentiated cells. By comparison, the Mad genes
are usually expressed in resting or differentiated cells with
little expression in dividing cells (13). A number of target genes
for c-Myc have been identified. Many of the target genes that
are up-regulated by c-Myc are either rate-limiting enzymes
involved in the biosynthesis and metabolic production of poly-
amines and pyrimidines, such as ornithine decarboxylase (14)
and cad (15), or involved in cell cycle control such as cdc25a
(16), ISGF3 (17), and p53 (18).
Pax-3 is a member of a family of evolutionarily conserved
transcription factors (19) that have been shown to play a crit-
ical role in early embryogenesis. Disruption of the Pax-3 gene
has been shown to lead to a range of developmental abnormal-
ities including neural tube defects, a lack of limb musculature,
and deficiencies in neural crest-derived cell types (20–24).
Pax-3, like N-myc, is first expressed during early embryogene-
sis within neural crest lineages, limb buds, and the developing
nervous system. The expression of Pax-3 in these tissues is
restricted to mitotically active progenitor cells and is rapidly
down-regulated upon differentiation (25, 26). Given the over-
lapping patterns of expression of N-myc and Pax-3, we have
examined the relationship between N-Myc and Pax-3, and in
this report we present evidence that Pax-3 is a direct transcrip-
tional target of N-Myc and c-Myc.
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EXPERIMENTAL PROCEDURES
Cell Culture—ND7, NIH3T3, and COS-7 cells were grown in full
growth medium containing Dulbecco’s modified Eagle’s medium
(DMEM),1 10% bovine calf serum, and 2 mM glutamine. Neuroblastoma
cell lines (IMR-32, Kelly, SK-N-SH, C1300, SHSY-5Y, SK-N-AS, SK-N-
BE, and SK-N-DZ) were grown in DMEM, 10% bovine calf serum, 2 mM
glutamine, and 1% nonessential amino acids.
Transfections—To prepared stable cell lines expressing N-Myc, ND7
cells (5 105) were plated out on 58-cm2 dishes and transfected with an
N-Myc expression vector (pMiwNmyc; 2 g) together with 2 g of
pcDNA3.1, which carries the neomycin resistance marker. Stable trans-
fectants were selected by supplementing the medium 48 h after trans-
fection with 800 g/ml G418. Independent clones were isolated after 1
week, when individual foci of cells were evident. These were then grown
up and maintained in DMEM plus 10% serum containing 800 g/ml
G418. Cell lines expressing c-MycER were generated by transfecting
ND7 cells with pBpuro c-MycER (27) and selecting for puromycin (5
g/ml)-resistant clones. The retroviral vector pBpuro c-MycER com-
prises the c-myc coding sequences fused in frame to a modified ligand
binding domain of the estrogen receptor. The fusion protein is activated
by the addition of the synthetic ligand 4-hydroxytamoxifen (OHT) but is
refractory to 17-estradiol. ND7 cells expressing c-MycER were pas-
saged in DMEM plus 10% bovine calf serum and 1% charcoal-treated
bovine calf serum for 48 h prior to Myc induction. To activate c-MycER,
100 nM OHT was added to the culture media for 4 h. This results in the
translocation of the c-MycER fusion protein from the cytoplasm to the
nucleus (data not shown). In transient transfection assays, NIH3T3,
ND7, and COS-7 (5  105) cells were plated out on 58-cm2 dishes and
transfected as previously described (28). The transfection efficiency was
normalized by co-transfecting cells with pCMV--gal. -Galactosidase
assays were performed according to the method of Gorman (29). Quan-
titation of the CAT assay was achieved using a STORM Phosphor-
Imager and then using an image quantifier program to calculate per-
centage conversions of the [14C]chloramphenicol to its acetylated prod-
ucts. For cell cycle analysis, transfected ND7 cells were placed in
serum-free media for 24 h. Following serum starvation, the cells were
either harvested or refed with media containing serum and incubated
for the indicated time periods. Luciferase assays were performed using
the Promega luciferase assay system.
Western Blot Analysis—Nuclear extracts were made as described by
Dignam et al. (30), and the protein concentration of each sample was
determined using the Bio-Rad DC protein assay kit. Samples (20 g of
nuclear protein) were separated by SDS-PAGE (7.5% resolving gel)
using a Bio-Rad minigel apparatus. Proteins were transferred to a
Hybond-P membrane and blocked overnight at 4 °C with 5% dried milk
powder, 0.02% Tween 20 in PBS. Membranes were incubated at room
temperature for 1 h at room temperature in 5% dried milk powder in
phosphate-buffered saline and a 1:2000 dilution of N-Myc or c-Myc
antisera and washed in phosphate-buffered saline plus 0.2% Tween 20.
Membranes were then incubated in phosphate-buffered saline plus
0.2% Tween 20 containing 5% dried milk powder with a 1:10,000 dilu-
tion of goat anti-rabbit antibody coupled to horseradish peroxidase for
1 h. Immunoreactive bands were then visualized using Ultrasignal
(Pierce), and the intensities of the bands were quantitated using den-
sitometry. All membranes were subsequently checked to ensure equal
loading of samples by staining the membrane with Amido Black.
Antibodies—Anti-c-Myc, -Max, -Mad, and -MyoD antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
N-Myc antibodies were from Calbiochem.
RT-PCR—Total cellular RNA was extracted using Trizol (Invitro-
1 The abbreviations used are: DMEM, Dulbecco’s modified Eagle’s
medium; OHT, 4-hydroxytamoxifen; RT, reverse transcriptase; EMSA,
electrophoretic mobility shift assay.
FIG. 1. Regulation of Pax-3 promoter activity by N-Myc and
c-Myc. Shown are a representative CAT assay (A) and graph (B) of
NIH3T3 cells co-transfected with the Pax-3 promoter (Pax3CAT; 2 g)
and either the null expression vector pMiSV (V, 4 g), N-Myc and Max
expression vectors (4 g each), N-Myc expression vector (4 g), Max
expression vector (4 g), c-Myc and Max (4 g each), or c-Myc expres-
sion vector (4 g). C and D, increasing the concentration of N-Myc-Max
or c-Myc-Max further enhanced Pax-3 promoter activity. The Pax-3
promoter construct (Pax3CAT; 2 g) was co-transfected with either
increasing concentrations of N-Myc-Max (2, 4, and 6 g) (C) or c-Myc-
Max (2, 4, and 6 g) (D) into NIH3T3 cells. The graph shows the mean
of four independent experiments  S.E. (all values are normalized for
pCMV--gal activity).
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gen), and RNA concentrations were determined by slot-blot hybridiza-
tion. Conventional RT-PCR was carried out as described by Reeves et al.
(26), with gene-specific primers for Pax-3 (5-GGAATACAAAGAGAG-
AACCCG-3 and 5-CTTCATCTCACTGAGGTGCG-3) and the house-
keeping gene cyclophilin (5-TTGGGTCGCGTCTGCTTCGA-3 and 5-
GCCAGGACCTGTATGCTTCA-3). For Taqman quantitative RT-PCR
analysis, all equipment and reagents were supplied by Applied Biosys-
tems. Taqman PCR primers and probes were designed using Primer
Express software. (Pax-3 forward primer, 5-GAGTGAGCGCGAGCCT-
CTGCAC-3; reverse primer, 5-AGGTGGTTCTGCTCCTGCG-3;
Taqman probe, 5-AGGCTCCGTATTGACTCTGAACCTGATTTACC-
3). Primers and probes for the housekeeping gene 18 S ribosomal RNA
FIG. 2. Identification of the sequences responsible for Myc-Max regulation of Pax-3 promoter activity. A, schematic diagram of the
region of the Pax-3 gene near the start site of transcription (CAP) to show the constructs tested for Myc-dependent activation. B, graph showing
the level of relative CAT activity in NIH3T3 cells co-transfected with either 2 g of Pax3CAT (bp 1578 to 56) or one of the Pax-3 promoter
deletion constructs, dK (bp 970 to 56), dS (bp 537 to 56), dA (bp 155 to 56), dX (bp 93 to 56), and either N-Myc and Max expression
vectors (4 g each) or c-Myc and Max expression vectors (4 g each). The level of Myc-Max activation was then expressed relative to the level of
CAT activity observed in cells transfected with Pax3CAT and a null expression vector. This was arbitrarily set at 1. Values represent the mean
of four independent experiments  S.E. (all values are normalized for pCMV--gal activity). C, sequence of the Pax-3 promoter from bp 155 to
93 upstream of the transcription start site. The locations of transcription factor binding sites identified in this region are underlined. D, graph
showing the level of relative CAT activity in NIH3T3 cells cotransfected with either 2 g of Pax3CAT or the Pax-3 promoter construct (EboxProm)
containing a mutated E box site together with either N-Myc-Max or c-Myc-Max (4 g each). Values represent the mean of four independent
experiments  S.E. (all values are normalized for pCMV--gal activity).
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were supplied by Applied Biosystems. Probes were labeled at the 5-end
with a 6-carboxyfluorescein reporter dye and at the 3-end with a
6-carboxytetramethylrhodamine quencher dye. To test the primer
pairs, conventional RT-PCR was used as described previously (26), and
amplified products were confirmed by direct sequencing of the PCR. For
Taqman PCR, cDNA was synthesized using 200 ng of total RNA in a
10-l reaction volume using RTGold reagents according to the manu-
facturer’s instructions. Taqman PCR was performed with 1 l (equiva-
lent to 10 ng of input RNA) of cDNA template in a 25-l PCR containing
100 nM primers, 50 nM probe in Universal Taqman master mix. Cycling
conditions were 50 °C for 2 min, 95 °C for 10 min followed by a 40-cycle
amplification cycle of 95 °C for 15 s and 60 °C for 1 min on the Applied
Biosystems PRISM 7700 sequence detection system. Samples were ana-
lyzed in duplicate and normalized to the measurement of the house-
keeping gene as described by Bustin et al. (31).
DNA Cloning—The Pax-3 promoter (1578 to56 bp) was amplified
from MF1 mouse genomic DNA by PCR using the primers 5-GAGCT-
CTAATGCTCCTCC-3 and 5-GGTGACGAGGCAGGAAC-3 and Accu-
Taq (Sigma). The amplified fragment was cloned into pGem-T Easy
(Promega) and sequenced. The Pax-3 promoter fragment was excised
from pGem-T Easy with SphI and SalI and subcloned into pCATBasic
(Promega) to create Pax3Cat or into pGL3Basic (Promega). Truncated
promoter constructs were made by digesting Pax3CAT with SphI and
either KpnI, SalI, AvaII, or XmaI. The digested vectors were then
purified and religated to form dK (970 to 56 bp), dS (537 to 56
bp), dA (155 to 56 bp), and dX (93 to 56 bp). All clones were then
sequenced to verify the construct. All deletion constructs used were able
to drive expression of a reporter gene. The expression vectors con-
taining N-myc (pmiwNmyc) and Max (pmiwMax) were a kind gift of H.
Kondoh. The c-myc cDNA clone was obtained from M. Green and sub-
cloned into pMisv. The vectors pBpuro and pBpuro cMycER were a kind
gift from G. Evan.
Site-directed Mutagenesis—The putative E box sequence in the Pax-3
promoter was mutated from CGCGTG to CCGCGG using two-step PCR
FIG. 3. N-Myc-Max and c-Myc-Max bind to the Pax-3 E box site in vitro. A, EMSA in which lysates of COS-7 cells transfected with
N-Myc-Max, Max, c-Myc-Max, or an empty expression vector (Con) were incubated with a radiolabeled oligonucleotide containing the Pax-3 E box
site. B, lysates from N-Myc-Max- and c-Myc-Max-transfected COS-7 cells were incubated with a radiolabeled oligonucleotide containing the Pax-3
E box site either alone or in the presence of specific antibodies (ab) to N-Myc, c-Myc, Max, or Mad. C and D, comparison of N-Myc-Max (C) and
c-Myc-Max (D) binding affinities by competition experiments. Binding to the radiolabeled Pax-3 E box sequence was competed with unlabeled
Pax-3 E box sequence (Pax-3 E box), the consensus E box site (Con E box), the cdc25 E box site (cdc25 E box), and a mutant E box site (Mut E Box)
at 0-, 10-, 50-, 100-, and 500-fold molar excess. Binding of uncompeted Pax-3 E box oligonucleotide was set to 100%.
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mutagenesis using the following primers: 5-CCCAATCAGCCGCG-
GTCTTTGCCAC-3 and 5-GTGGCAAAGACCGCGGCTGATTGGG-3.
The sequence of all clones was verified by sequencing.
Electrophoretic Mobility Shift Assays—Oligonucleotides for use in
electrophoretic mobility shift assays were annealed by heating to 85 °C
for 3 min and labeled using [-32P]ATP and polynucleotide kinase
(Promega). The oliognucleotides used were the Pax-3 E box Myc se-
quence (5-GCCCAATCAGCGCGTGTCTTTGCCAC-3), a consensus E
box Myc sequence (5-GGAAGCAGACCACGTGCTCTGCTTCC-3), the
cdc25 E box sequence (5-ACTACACACGTGCCACCACACCCAA-3),
and a mutant E box Myc sequence (5-GGAAGCAGACCACGGAGTCT-
GCTTCC-3). Nuclear extracts were made using the method described
by Dignam et al. (30). Electrophoretic mobility shift assays were carried
out as previously described (26). Competitions were performed using a
10-, 50-, 100-, and 500-fold excess of unlabelled oligonucleotide, which
was incubated with the nuclear extracts prior to the addition of the
probe. To confirm the identity of the retarded complex, nuclear extracts
were also incubated on ice for 4 h with 2 l of 1 g/ml specific antiserum
prior to the addition of the probe.
Cell Cycle Analysis—For cell cycle distribution, cells were pelleted
and resuspended in 1 ml of 0.1% Triton X-100, 0.1% sodium citrate, and
50 g/ml propidium iodide and incubated at 4 °C for 1 h. DNA content
was analyzed by flow cytometry (32) using a Becton Dickinson FACS-
Calibur flow cytometer. The analysis of cells in late G1 was confirmed by
arresting cells at the G1/S border with Aphidicolin, and the analysis of
G2/M cells was confirmed by arresting cells with hydroxyurea. For cell
synchronization, cells were seeded onto 8.7-cm2 Petri dishes at a den-
sity of 2 104. Cells were then serum starved by the addition of DMEM
plus 1 mM glutamine media for 24 h. Serum was then added back for 1,
3, 6, 12, and 18 h, and samples were analyzed for DNA content, c-Myc
and N-Myc protein levels, and Pax-3 mRNA levels.
RESULTS
Regulation of Pax-3 Promoter Activity by N-Myc and
c-Myc—To determine whether Pax-3 expression is regulated by
N-Myc, the 5 promoter region of the murine Pax-3 gene (bp
1578 to 56) was amplified by PCR from mouse genomic
DNA and sequenced. This region of the Pax-3 promoter has
been shown by Natoli et al. (33) to be sufficient for the correct
induction of Pax-3 expression in vivo. For our experiments, the
Pax-3 promoter (bp 1578 bp to 56) was then cloned up-
stream of the reporter gene CAT in the vector pCATbasic
(Pax3CAT). The Pax-3 promoter construct was then transiently
transfected into the fibroblast cell line NIH3T3 together with
an expression vector containing either the full-length cDNA of
the mouse N-myc gene or the full-length cDNA of the c-myc
gene. CAT activity was measured 48 h later. All transient CAT
assay values were normalized with a cotransfected cytomega-
lovirus- galactosidase plasmid. We found that co-transfection
of the Pax-3 promoter construct with either N-Myc or c-Myc led
to the induction of Pax-3 promoter activity. N-Myc induced an
18-fold increase, whereas c-Myc induced an 8-fold increase in
Pax-3 promoter activity (Fig. 1, A and B). Co-transfection of the
Pax-3 promoter with N-Myc and Max or c-Myc and Max led to
a further increase in Pax-3 promoter activity. In contrast, co-
transfection of Max alone with Pax-3CAT led to a small inhi-
bition in Pax-3 promoter activity (Fig. 1, A and B). In addition,
when the amounts of expression vectors for N-Myc-Max and
c-Myc-Max were increased in a fixed Myc/Max ratio, expression
of the Pax-3 promoter was further increased (Fig. 1C), suggest-
ing that members of the Myc family of transcription factors can
activate Pax-3 promoter activity in vitro. The expression of
pCATbasic was unaffected by the addition of increasing
amounts of N-Myc-Max or c-Myc-Max.
Myc Regulation of Pax-3 Expression Is Dependent upon Se-
quences in the Promoter of Pax-3—Having shown that the Myc
family of transcription factors is capable of regulating Pax-3
expression in transient transfection assays, we next investi-
gated whether this regulation was dependent on the direct
binding of the Myc proteins to sites within the Pax-3 promoter.
To test this, a series of truncated Pax-3 promoter constructs
derived from the Pax-3CAT promoter construct (bp 1578 to
56) were generated (Fig. 2A). All truncated promoter con-
structs were able to direct basal gene expression, and we there-
fore examined the ability of N-Myc-Max and c-Myc-Max to
activate each truncated construct. We found that all of the
truncated Pax-3 promoter constructs were activated in the
presence of both N-Myc and Max and c-Myc and Max, apart
from the smallest construct, dX (93 to 56 bp), which was no
longer activated by either N-Myc-Max or c-Myc-Max (Fig. 2B).
This suggests that the sequences between 155 and 93 bp
are essential for Myc regulation of Pax-3 expression. Computer
analysis of this region of the Pax-3 promoter, using Matinspec-
tor, version 2.2, based on Transfac 4.0, revealed an inverted
Myc E box binding site (CGCGTG) located 110/105 bp up-
stream of the transcription start site (Fig. 2C). Mutation of this
site from CGCGTG to CCGCGG abolished the ability of N-Myc
and Max or c-Myc and Max to activate Pax-3 promoter activity
(Fig. 2D).
The Pax-3 E Box Motif Is Bound by Myc and Max—To deter-
mine whether N-Myc-Max or c-Myc-Max heterodimers can bind
to the E box site from the Pax-3 promoter, whole cell extracts
from COS-7 cells transiently transfected with expression vec-
FIG. 4. Myc-Max binding to the Pax-3 E box site in neuronal cells. A, EMSA showing nuclear extracts (5 g) from dividing ND7 cells
incubated with a radiolabeled oligonucleotide containing the Pax-3 E box site either alone (ND7) or together with an excess of cold E box
olgonucleotide (ND7 100 Ebox) or with an excess of cold mutant E box sequence (ND7 100 Emut). B, EMSA showing that Pax-3 E box binding
in dividing ND7 is reduced by the addition antibodies raised against N-Myc, Max, and c-Myc. Nuclear extracts from ND7 cells were incubated with
radiolabeled E box probe either alone (), or with antibodies against MyoD, Mad, N-Myc, c-Myc, or Max. C, EMSA showing the decline in E box
binding in ND7 cells upon serum starvation. Nuclear extracts (5 g) were prepared from dividing ND7 cells (ND7) and from serum-starved ND7
cells (ND7 ss) and incubated with the radiolabeled Pax-3 E box probe and analyzed by EMSA.
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tors containing N-Myc, c-Myc, and Max were incubated with a
radiolabeled oligonucleotide containing the Pax-3 E box se-
quence, and DNA binding was assessed by an electrophoretic
mobility shift assay (34). In COS-7 cells transfected with an
empty expression vector, little binding to the Pax-3 E box site
was observed. In COS-7 cells transfected with N-myc expres-
sion vectors, no E box binding above that seen in control cells
was observed (data not shown). However, when COS-7 cells
were co-transfected with N-Myc and Max, one major retarded
complex was seen together with a very weak high mobility
complex (Fig. 3A). In COS-7 cells transfected with both N-Myc
and Max, the major retarded complex was disrupted by both
N-Myc and Max antibodies, suggesting that this major E box
complex represents N-Myc-Max binding to the Pax-3 E box
FIG. 5. Pax-3 mRNA levels are elevated in NMYC-amplified neuroblastoma cell lines. A, Western blot analysis to determine the level of
NMYC protein expressed in the neuroblastoma cell lines SK-N-SH, C1300, SHSY-5Y, SK-N-AS, SK-N-BE, SK-N-DZ, IMR-32, and Kelly. B,
quantitative RT-PCR analysis of Pax-3 mRNA expression in neuroblastoma cell lines. Values are the mean of three independent experiments 
S.E. Levels of Pax-3 mRNA are expressed relative to the level of Pax-3 expression detected in SK-N-SH cells, which is set to 1. All values have been
normalized to the measurement of 18 S rRNA. C, determination of Pax-3 mRNA levels in N-Myc-transfected mouse neuroblastoma cells. ND7 cells
were co-transfected with expression vector pMiSV-N-myc and pcDNA3.1. Five individual clones resistant to G418 were selected and named NM1
to -5. The cell lines were then analyzed for N-Myc protein expression by Western blot analysis (C) and for Pax-3 mRNA expression by quantitative
RT-PCR (D). Values are the means of three independent experiments  S.E. Levels of Pax-3 mRNA are expressed relative to the level of Pax-3
expression detected in the ND7 cell line transfected with an empty expression vector (V1), which is set to 1. All values have been normalized to
the measurement of 18 S rRNA.
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sequence. The weaker complex, however, was disrupted only by
antibodies against Max, suggesting that this weak E box bind-
ing represents Max homodimer binding (Fig. 3B). The faster
migrating E box complex was also observed in lysates from
COS-7 cells transfected with Max-containing expression vec-
tors, which is consistent with this complex representing Max
homodimer binding. We also found that c-Myc, like N-Myc,
could not bind to the E box motif alone, but, when transfected
with Max, binding was observed. These experiments suggest
that Max homodimers and N-Myc-Max and c-Myc-Max het-
erodimers can bind to the Pax-3 E box motif in vitro.
To compare the binding affinity of N-Myc-Max and c-Myc-
Max for the Pax-3 E box motif, competition assays were per-
formed using the consensus E box Myc sequence (CACGTG),
the E box site from the cdc25 gene, or a mutant E box site. In
these experiments, the radiolabeled Pax-3 E box oligonucleo-
tide was used as a probe with extracts from COS-7 cells, trans-
fected with either N-Myc-Max or c-Myc-Max, and incubated
with a 10-, 50-, 100-, or 500-fold molar excess of unlabeled
oligonucleotide. The addition of a 500-fold excess of the cold
Pax-3 E box site reduced binding by 85 and 61% with N-Myc-
Max and c-Myc-Max, respectively (Fig. 3, C and D). The con-
sensus E box motif and the E box site from the cdc25 gene were
able to effectively compete out N-Myc-Max and c-Myc-Max
binding, although both the consensus E box and the cdc25 E
box site were more effective in binding out c-Myc-Max rather
than N-Myc-Max binding. An oligonucleotide containing a mu-
tated Pax-3 E box site was not able to effectively compete out
N-Myc-Max or c-Myc-Max binding to the probe (Fig. 3, C and
D). These experiments demonstrate that both N-Myc-Max and
c-Myc-Max heterodimers can effectively bind to the E box motif
in the Pax-3 promoter, although N-Myc-Max heterodimers ap-
pear to bind to the Pax-3 E box site with greater affinity than
c-Myc-Max.
Examination of Myc-Max Binding to the Pax-3 E Box Site in
Neuronal Cells—Having shown that transiently transfected
N-Myc-Max and c-Myc-Max heterodimers can bind to the Pax-3
E box motif in COS-7 cells, the Pax-3 E box sequence was
examined for potential binding to Myc-Max heterodimers in the
ND7 cell line. To examine this, nuclear extracts were prepared
from the ND7 cell line. These cells proliferate indefinitely in
the presence of serum, but upon serum starvation, the cells
undergo cell cycle arrest and morphologically differentiate into
a mature neuronal-like phenotype. Dividing ND7 cells express
Pax-3 mRNA, but upon differentiation, the level of Pax-3 de-
clines. We found when nuclear extracts from dividing ND7 cells
were incubated with a radiolabeled oligonucleotide containing
the Pax-3 E box site and analyzed by EMSA, one low mobility
E box-binding protein was observed (Fig. 4A). Moreover, this
binding was specific, since E box binding was competed out by
an excess of oligonucleotide containing the E box site but not by
an oligonucleotide containing a mutant E box consensus se-
quence. Furthermore, the addition of antibodies raised against
N-Myc and Max dramatically reduced biding. Interestingly, the
addition of antibodies raised against c-Myc also reduced bind-
ing (Fig. 4B). Since the c-Myc antibody is specific for c-Myc and
does not cross-react with other members of this family (data
not shown), this suggests that in dividing ND7 cells, the E box
site within the Pax-3 promoter is bound by a combination of
N-Myc-Max and c-Myc-Max complexes. Western blot analysis
confirmed that ND7 cells express both N-Myc and c-Myc pro-
teins (see Fig. 7). In contrast, antibodies against Mad or MyoD,
had no effect on E box binding (Fig. 4B). Interestingly, in
serum-starved ND7 cells, little c-Myc-Max binding to the E box
site was observed (Fig. 4C).
Expression of Pax-3 mRNA in NMYC-amplified Neuroblas-
toma Cell Lines—Having shown that N-Myc and c-Myc can
regulate Pax-3 promoter activity, we next examined the possi-
bility that Pax-3 expression may be regulated by members of
the Myc family of transcription factors in vivo. If Pax-3 is a
target gene of N-Myc, then expression of Pax-3 mRNA would be
expected to be altered in cell lines encoding an amplified NMYC
gene. We therefore analyzed the expression of Pax-3 mRNA in
a range of neuroblastoma cell lines containing either a single
copy NMYC gene (SK-N-SH, C1300, SHSY-5Y, and SK-N-AS)
or an amplified NMYC gene (IMR-32, Kelly, SK-N-DZ, and
SK-N-BE) (2). We found, as shown in Fig. 5A, that all cell lines
expressed detectable levels of NMYC protein, with the highest
levels of NMYC being detected in Kelly, IMR-32, SK-N-DZ, and
SK-N-BE cell lines. These are the cell lines with an amplified
NMYC gene. Quantitative RT-PCR analysis revealed that lev-
els of Pax-3 mRNA correlated with levels of NMYC protein,
with Kelly and IMR-32 cells expressing the highest levels of
Pax-3 mRNA; SK-N-BE and SK-N-DZ cell lines expressing
intermediate levels of Pax-3 mRNA; and the lowest levels of
Pax-3 mRNA being detected in the neuroblastoma cell lines
with a single copy NMYC gene (SK-N-SH, C1300, SHSY-5Y,
and SK-N-AS) (Fig. 5B).
To investigate this link between N-Myc and Pax-3 mRNA
expression further, the mouse neuroblastoma cell line ND7 was
FIG. 6. Expression of c-MycER in ND7 cells. A, Western blot
analysis of cell lysates prepared from two vector-transfected cell lines
(V1 and V2) and from two c-MycER-transfected cell lines (ER1 and
ER2). B, quantitative RT-PCR analysis of RNA extracted from the cell
lines V1, V2, c-MycER1, and c-MycER2. The cells were treated with or
without OHT (100 nM) for 4 h prior to harvesting. Values are the mean
of three independent experiments  S.E. Levels of Pax-3 mRNA are
expressed relative to the level of Pax-3 expression detected in V1 cells
without OHT treatment. This is set to 1. All values have been normal-
ized to the measurement of 18 S rRNA.
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transfected with an expression vector containing a full-length
N-myc cDNA. Five independent G418-resistant cell lines were
selected by stable transfection and grown up for further anal-
ysis. We found that in the cells transfected with the N-myc
expression vector (NM1–5), the level of N-Myc protein was
2–7-fold higher than that observed in control cells (V1), which
were stably transfected with the empty expression vector (Fig.
5C). Pax-3 mRNA levels were also increased in the cell lines
overexpressing N-Myc, with the highest levels of Pax-3 mRNA
being detected in the cell lines NM2, NM3, and NM4. These cell
lines also express the highest levels of N-Myc protein (Fig. 5D).
These results suggest that the ectopic expression of N-Myc
leads to an elevation in endogenous Pax-3 mRNA expression.
Since we have shown that c-Myc can also bind to the Pax-3 E
box motif, albeit with lower affinity than N-Myc-Max het-
erodimers, we next investigated whether Pax-3 mRNA levels
were increased in cell lines ectopically expressing c-Myc. How-
ever, despite repeated attempts, we failed to produce cell lines
constitutively overexpressing c-Myc. However, ND7 cell lines
expressing c-MycER, a conditional form of c-Myc, were estab-
lished (Fig. 6), and these cell lines were then examined to
determine whether c-Myc activation induced by the addition of
OHT led to an increase in Pax-3 mRNA levels. We found that in
the activated c-MycER cell lines, Pax-3 mRNA levels did in-
crease (Fig. 6B), supporting the hypothesis that Pax-3 expres-
sion is regulated by members of the Myc family of transcription
factors in vivo.
Pax-3 mRNA Expression in Neuronal Cells Is Cell Cycle-
dependent—Pax-3 mRNA expression was also examined under
conditions where the expression of Myc proteins is known to be
modulated. Both c-Myc RNA and protein levels are known to
oscillate during the cell cycle (35); we therefore compared the
levels of Myc expression and the levels of Pax-3 mRNA during
the different phases of the cell cycle in the ND7 cell line. To do
this, ND7 cells were synchronized by serum starvation for 24 h.
The cells were then released from this cell cycle block by the
addition of serum back to the cells. Samples were taken at 0, 1,
3, 6, 12, and 18 h after the addition of serum back to the cells
and analyzed for DNA content by flow cytometry, analyzed for
c-Myc and N-Myc protein expression by Western blot analysis,
and analyzed for Pax-3 mRNA level by RT-PCR (Fig. 7). We
found that in growth-arrested ND7 cells, no expression of
N-Myc or c-Myc protein could be detected (Fig. 7). However,
within 1 h of the addition of serum to the growth-arrested cells,
levels of N-Myc and c-Myc protein rose, and the expression of
both N-Myc and c-Myc peaked at 3 h after serum addition,
before progressively declining through S phase and G2/M (Fig.
7A). Interestingly, Pax-3 mRNA levels also oscillated through
the cell cycle. No expression of Pax-3 mRNA was detected in the
growth-arrested cells; however, within 1 h of the addition of
serum, low levels of Pax-3 mRNA were detected, and by 6 h
after serum addition, high levels of Pax-3 mRNA were detected.
Levels of Pax-3 mRNA levels then subsequently declined as the
majority of the cells entered S phase (Fig. 7B). Interestingly,
the peak in Pax-3 expression lagged behind the peak in N-Myc
and c-Myc protein expression by 1–3 h, which would be con-
sistent with Pax-3 expression being regulated by N-Myc or
c-Myc.
Mutation of the Myc E Box Site Changes Pax-3 Cell Cycle
Expression—To determine whether members of the Myc family
of transcription factors are responsible for the cell cycle-
dependent expression of Pax-3 mRNA, the 5 promoter region
(bp 1578 to 56) of the Pax-3 gene was fused upstream of the
reporter gene luciferase in the vector pGL3Basic. ND7 cells
were transiently transfected with this construct (Pax3-Luc)
together with pCMV--gal and synchronized by serum starva-
tion. The transfected cells were then released from their cell
cycle block by the addition of serum, and samples were taken at
0, 1, 3, 6, 12, 18, and 24 h after serum addition and analyzed for
luciferase activity, -galactosidase activity, and DNA content.
We found, as shown in Fig. 8, that the expression of Pax3-Luc
peaked 6 h after serum addition, before expression decreased
FIG. 7. Pax-3 mRNA expression oscillates during the cell cycle. ND7 cells were synchronized by serum starvation for 24 h. The cells were
then released from the cell cycle block by the addition of serum, and cells were analyzed 0, 1, 3, 6, 12, and 18 h after the addition of serum for the
level of N-Myc and c-Myc protein expression by Western blot analysis (A), for Pax-3 and cyclophilin mRNA expression by RT-PCR (B), and for the
percentage of cells in G0/G1, S, or G2/M phase at the indicated time points (C).
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through S phase. This pattern of cell cycle expression corre-
sponds precisely with the time course of expression of endoge-
nous Pax-3 mRNA during the cell cycle and suggests that all of
the necessary elements involved in the cell cycle expression of
Pax-3 are located within the region bp 1578 to 56 of the
Pax-3 promoter. In contrast, no change was observed in the
expression of pSV-Luc, as previously reported by Slansky et al.
(36) (Fig. 8A) or in pGl3basic expression (data not shown). To
determine whether the E box Myc sequence at 110 bp of the
Pax-3 promoter is required for the cell cycle expression of the
reporter construct Pax3-Luc, the Pax-3 promoter bearing
the mutant E box site was fused upstream of the luciferase
gene in pGL3Basic, and the expression of this construct was
compared with the wild type promoter through the different
phases of the cell cycle. Interestingly, we found that the level of
luciferase activity in the growth-arrested cells transfected with
the mutant Pax-3 promoter was higher than that observed in
cells transfected with the wild type promoter, suggesting that
the E box site in the wild type promoter has an inhibitory effect
on Pax-3 expression in growth-arrested cells. We also found
that the expression of the mutant Pax-3 promoter construct did
oscillate during the cell cycle (Fig. 8A); however, both the level
of induction and the timing of expression were different in cells
transfected with the mutant promoter compared with the wild
type promoter. In cells transfected with the mutant promoter,
a small peak in luciferase activity occurred 10–12 h after the
addition of serum, coinciding with the onset of S phase. This
compares with a peak in luciferase activity 6 h after the serum
addition in cells transfected with the wild type promoter. These
results suggest that the E box binding site located at 110 bp
upstream of the transcription start site in the Pax-3 promoter
plays an important role both in the repression of Pax-3 expres-
sion in growth-arrested cells and in the induction of Pax-3
expression in the G1 phase of the cell cycle.
DISCUSSION
In this report, we have identified the developmental control
gene Pax-3 as a novel transcriptional target of the Myc family
of transcription factors. We have shown in transient co-trans-
fection assays that both N-Myc and c-Myc enhanced the activ-
ity of the Pax-3 promoter by 18- and 8-fold, respectively. The
transcriptional activation of the Pax-3 promoter was further
enhanced by the co-transfection of N-Myc and c-Myc with their
dimerization partner Max. The ability of N-Myc or c-Myc to
activate the Pax-3 promoter in the absence of transfected Max
probably reflects the fact that NIH3T3 cells express endoge-
nous Max, which may form heterodimers with the transfected
Myc proteins. The transfection of Max, in the absence of N-Myc
or c-Myc, in contrast, led to a small reduction in Pax-3 promoter
activity. Since Max proteins have been reported not to interact
with the Sin3 transcriptional repressor proteins (37), Max
probably inhibits Pax-3 promoter activity by competing for the
Pax-3 E box site with endogenous Myc-Max heterodimers.
The Myc-Max-Mad network of transcriptional regulators has
been shown to modulate gene expression through a subset of E
box motifs, which have the core consensus sequence CACGTG
(9, 10). Most of the Myc specific E box elements identified to
date are found downstream of the transcription initiation site
either within the first or second intron or in the 5-untranslated
region or within the protein coding sequence (15, 16, 38, 39).
Only the EIF-4E (40), LDH-A (41), and ISGF3 (17) genes
contain E box sites within the 5 promoter region. Deletion and
mutagenesis experiments have shown that the Pax-3 gene con-
tains an inverted E box sequence CGCGTG (CACGCG) in the 5
promoter region that is responsible for Myc regulation of Pax-3
promoter activity. This inverted E box sequence differs by 1 bp
from the consensus E box sequence CACGTG. However, we
found that both c-Myc-Max and N-Myc-Max complexes bind to
the Pax-3 E box site. This is consistent with site selection
studies by Blackwell et al. (42), who found that c-Myc-Max
heterodimers could bind in vitro to a set of variant E box sites
including CACGCG, CATGTG, CATGCG, CACGAG, and
CAACGTG, which are referred to as noncanonical E box se-
quences. Although c-Myc-Max complexes were shown in gen-
eral to bind with lower affinity to these noncanonical sites than
to the consensus site, Blackwell et al. (42) did show that c-Myc-
Max complexes bound to the noncanonical site CACGCG al-
most as well as to the Myc E box consensus site. Furthermore,
chromatin immunoprecipitation experiments have revealed
that the most common in vivo Myc binding sites are noncanoni-
cal E box sequences (39). Grandori et al. (39) also demonstrated
that noncanonical E box sequences could, when cloned in a
forward or reverse orientation upstream of the thymidine ki-
FIG. 8. Induction of the Pax-3 promoter through the cell cycle.
The reporter plasmids Pax3-Luc and Pax3Emut-Luc containing either
the wild type or mutant E box site, respectively, were transfected with
pCMV--gal into ND7 cells. The cells were placed in 0% serum for 24 h
after the removal of the calcium phosphate precipitates. The cells re-
mained in 0% serum media for 24 h to induce quiescence, at which point
serum was added back to the cells (time 0). At the indicated time points,
cells were removed for cell cycle analysis by flow cytometry and for the
determination of luciferase and -galactosidase activity. A, luciferase
values for a representative experiment (normalized for -galactosidase
activity). The reporter plasmid Sv-Luc was also analyzed as a control. B,
percentage of cells in S phase and G2/M phase at the indicated time
points.
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nase promoter, confer Myc-dependent transcription on a re-
porter gene.
In ND7 cells, DNA binding studies showed strong binding to
the Pax-3 E box motif. Moreover, E box binding was reduced by
antibodies directed against N-Myc, c-Myc, and Max, suggesting
that in ND7 cells, the E box motif is bound by a combination of
N-Myc-Max and c-Myc-Max. Both N-Myc and c-Myc are ex-
pressed in ND7 cells. Interestingly, the level of Myc-Max bind-
ing to the E box motif decreased in nondividing ND7 cells. This
is consistent with previous reports that show that N-Myc and
c-Myc expression is confined to mitotically active cells. Inter-
estingly, however, in serum-starved cells, we could not detect
any Mad/Max binding to the E box site. This may be due to the
very low activity of Mad in serum-starved ND7 cells or due to
the fact that Mad-Max complexes are distributed into many
distinct complexes in nondividing cells, which might not be
detected individually (34). This suggestion is based on the
findings that Mad1 interacts with Sin3 proteins in vivo and
Sin3 binds to a number of additional proteins such as histone
deacetylases and NCo-R.
Studies by Malynn et al. (43) have demonstrated a major
degree of functional redundancy between the N-Myc and c-Myc
proteins. They were able to show that mice (c-mycn/n) in which
the c-myc coding sequences had been replaced with N-myc
coding sequences survived into adulthood and reproduced.
However, there were differences between c-mycn/n mice and
controls; the overall survival of postnatal c-mycn/n mice was
modestly reduced compared with wild type, the average weight
of c-mycn/n mice was also lower than controls, and dystrophy of
skeletal muscles was observed in a subset of c-mycn/n mice.
These differences observed between c-mycn/n mice and wild
type mice suggest that subtle differences between N-Myc and
c-Myc exist. This is consistent with the fact that although there
is considerable amino acid sequence homology between N-Myc
and c-Myc, there are regions unique to N-Myc. Interestingly,
we found that N-Myc-Max complexes bound with higher affin-
ity to the Pax-3 E box site than c-Myc-Max. Differences in DNA
binding specificity between c-Myc-Max and N-Myc-Max has
been previously reported by Prochownik and VanAntwerp (44),
who demonstrated that c-Myc-Max and N-Myc-Max exhibited
distinct preferences for 5- and 3-flanking dinucleotides.
N-Myc-Max bound preferentially to the core consensus when
flanked at the 5-end by GA and at the 3-end by CT, whereas
c-Myc-Max preferred AC at the 5-end and GT at the 3-end
(44). Interestingly, the Pax-3 E box site is flanked by a 5-GA
and a 3-CT, the dinucleotides preferred by N-Myc-Max. It will
be important to determine whether in vivo the E box motif in
the Pax-3 promoter is bound preferentially by N-Myc-Max or
c-Myc-Max. A number of other potential N-Myc target genes
have been identified. These include activin A (45), NCAM (46),
Ndr1 (47), and insulin-like growth factor receptor (48); how-
ever, the sequence motifs responsible for N-Myc-dependent
regulation of these genes have yet to be identified.
The finding that Myc-Max heterodimers can bind to the E
box site in the Pax-3 promoter at least in vitro raises the
possibility that Pax-3 expression in vivo may be regulated by
members of the Myc family of transcription factors. In support
of this hypothesis, we have shown that Pax-3 mRNA expression
was elevated in a number of NMYC-amplified neuroblastoma
cell lines. The elevation of Pax-3 mRNA expression in neuro-
blastoma cell lines with an amplified NMYC gene is intriguing;
however, only a limited number of neuroblastoma cell lines
have been examined, and it will be important to determine the
extent of this correlation and the contribution that Pax-3
makes to the pathogenesis of neuroblastoma by examining
Pax-3 mRNA levels in a large series of primary neuroblasto-
mas. It is interesting to note, however, that Pax-3 mRNA has
also been reported in other neural crest lineage tumors includ-
ing melanomas (49, 50), where Pax-3 expression has been
shown to be essential for tumor cell survival (50). However,
whether amplification of Myc in these tumors correlates with
increased Pax-3 expression remains to be determined. In our
experiments, we also detected elevated levels of Pax-3 mRNA
in a series of cell lines ectopically expressing N-Myc. Interest-
ingly, attempts to create ND7 cell lines ectopically expressing
c-myc from a constitutive promoter consistently failed. Cell
lines were produced, however, using the conditional form of
c-Myc, cMycER. Moreover, the activation of c-MycER by OHT
led to increased Pax-3 mRNA expression. This suggests that
the ectopic expression of c-Myc, like N-Myc, can induce in-
creased expression of Pax-3 mRNA.
If Pax-3 is an in vivo target gene of the Myc family of
transcription factors, then Pax-3 expression should not only be
elevated in cell lines overexpressing Myc, but Pax-3 mRNA
levels should also be modulated under conditions where expres-
sion of Myc is altered. We found that Pax-3 mRNA expression
did oscillate during the cell cycle, as does N-Myc and c-Myc
expression Moreover, whereas a peak in c-Myc and N-Myc
expression was observed 3 h after the addition of serum, early
in G1, a peak in Pax-3 mRNA levels was observed 6 h after
serum addition. This lag between the increase in Myc expres-
sion and Pax-3 expression is consistent with the suggestion
that Pax-3 is a target gene for the Myc family of transcription
factors and with previous reports that show that the expression
of other Myc target genes such as cad (15) are also induced like
Pax-3 in late G1. Using reporter constructs, we were also able
to show that all of the necessary cis-acting elements required
for Pax-3 cell cycle expression are contained within the 5
region of the Pax-3 promoter from bp 1578 to 56. Interest-
ingly, mutation of the E box site within the Pax-3 promoter
significantly altered the pattern of expression of the reporter
construct in cycling cells. In cells transfected with the mutant
promoter, a peak in luciferase activity was not observed until S
phase. Furthermore, the magnitude of the peak was much
smaller than observed with the wild type promoter, suggesting
that Myc binding proteins play an important role in modulat-
ing the cell cycle-dependent expression of Pax-3. We also ob-
served that the level of expression of the mutant Pax-3 pro-
moter was substantially higher than the wild type promoter in
the growth-arrested cells. This finding implies that the E box
motif in the Pax-3 promoter is bound by inhibitory factors in
growth-arrested cells. Such E box binding inhibitory factors
may comprise the Mad family of proteins, which have been
shown to be highly expressed in growth-arrested cells and may
therefore play a role in the down-regulation of Pax-3 expression
in nondividing cells. Together, these data suggest that Pax-3
cell cycle expression is modulated through the noncanonical E
box motif in the promoter of Pax-3; however, further experi-
ments that show that dominant negative myc mutants (51, 52)
abolish Pax-3 cell cycle-regulated expression are required to
directly implicate Myc in the cell cycle-dependent expression of
Pax-3.
What is the functional significance of Myc regulation of
Pax-3 expression? Pax-3 has been suggested to play roles in cell
proliferation, differentiation, and/or in cell migration. The find-
ing that Pax-3 expression is modulated by the Myc and the
observation that Pax-3 expression is cell cycle-regulated fur-
ther support a role for Pax-3 in early proliferation events dur-
ing embryogenesis. The link between Pax-3 and the cell cycle is
intriguing, since recent studies by O’Wiggan et al. (53) have
shown that Pax-3 strongly interacts with the gene product of
the retinoblastoma tumor suppressor gene pRB (53). The pRB
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family of proteins, which include pRB, p107, and p130, are
negative regulators of cell cycle progression. In quiescent cells,
pRB is unphosphorylated and interacts with the transcription
factor E2F. This interaction inhibits the transcription of E2F-
responsive genes, which are essential for cell cycle progression
(for a review, see Ref. 54). When cells are stimulated with
serum, pRB is phosphorylated and releases free E2F, which is
then able to activate its target genes and promote cell cycle
progression. Pax-3 also preferentially associates with the un-
phosphorylated form of pRB, and this association between
Pax-3 and pRB, as with E2F, inhibits the ability of Pax-3 to
activate its target genes. Thus, both Pax-3 mRNA expression
and transactivation ability appear to be cell cycle-dependent,
strongly suggesting a role for Pax-3 in cell cycle progression
and/or in coordinating cell proliferation and differentiation
events.
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